Delving into the Latest Updates on Guangzhou Ruifeng Biological Technology Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Congenital Disorders

Eye Diseases

CRISPR/Cas

AAV based gene therapy

Gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Endocrinology and Metabolic Disease	2
Immune System Diseases	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

CRISPR/Cas	3
AAV based gene therapy	2
Hematopoietic stem cell therapy	1
Gene editing	1
Gene therapy	1

Top 5 Target	Count

VEGFR2(Vascular endothelial growth factor receptor 2)	1
HBA2(hemoglobin subunit alpha 2)	1
PTBP1 x ROCK	1
AQP1(aquaporin 1 (Colton blood group))	1
HBG1(hemoglobin subunit gamma 1)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

IND Approval

1

2

Phase 1 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

RM-004	Alpha-Thalassemia More	Phase 1 Clinical
HBG gene modified autologous CD34+ hematopoietic stem cells(Guangzhou Ruifeng) ( HBG1 )	Transfusion-dependent Beta Thalassemia More	Phase 1
RM-101 ( HBG1 x usherin )	Usher Syndrome type 2 More	IND Approval
RM-102	Diabetic macular oedema More	Preclinical
HBA2 targeted Gene editing (Ruifeng) ( HBA2 )	Alpha-Thalassemia More	Preclinical